{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T14:09:55Z","timestamp":1764079795467,"version":"3.41.2"},"reference-count":38,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>Antibiotic-resistant bacterial pathogens are a very challenging problem nowadays. <jats:italic>Helicobacter pylori<\/jats:italic> is one of the most widespread and successful human pathogens since it colonizes half of the world population causing chronic and atrophic gastritis, peptic ulcer, mucosa-associated lymphoid tissue-lymphoma, and even gastric adenocarcinoma. Moreover, it displays resistance to numerous antibiotics. One of the <jats:italic>H. pylori<\/jats:italic> pivotal transcription factors, HP1043, plays a fundamental role in regulating essential cellular processes. Like other bacterial transcription factors, HP1043 does not display a eukaryote homolog. These characteristics make HP1043 a promising candidate to develop novel antibacterial strategies. Drug repositioning is a relatively recent strategy employed in drug development; testing approved drugs on new targets considerably reduces the time and cost of this process. The combined computational and <jats:italic>in vitro<\/jats:italic> approach further reduces the number of compounds to be tested <jats:italic>in vivo<\/jats:italic>. Our aim was to identify a subset of known drugs able to prevent HP1043 binding to DNA promoters. This result was reached through evaluation by molecular docking the binding capacity of about 14,350 molecules on the HP1043 dimer in both conformations, bound and unbound to the DNA. Employing an ad hoc pipeline including MMGBSA molecular dynamics, a selection of seven drugs was obtained. These were tested <jats:italic>in vitro<\/jats:italic> by electrophoretic mobility shift assay to evaluate the HP1043\u2013DNA interaction. Among these, three returned promising results showing an appreciable reduction of the DNA-binding activity of HP1043. Overall, we applied a computational methodology coupled with experimental validation of the results to screen a large number of known drugs on one of the <jats:italic>H. pylori<\/jats:italic> essential transcription factors. This methodology allowed a rapid reduction of the number of drugs to be tested, and the drug repositioning approach considerably reduced the drug design costs. Identified drugs do not belong to the same pharmaceutical category and, by computational analysis, bound different cavities, but all display a reduction of HP1043 binding activity on the DNA.<\/jats:p>","DOI":"10.3389\/fmolb.2022.887564","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T05:25:55Z","timestamp":1652246755000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeting the Essential Transcription Factor HP1043 of Helicobacter pylori: A Drug Repositioning Study"],"prefix":"10.3389","volume":"9","author":[{"given":"Federico","family":"Antoniciello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Davide","family":"Roncarati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annamaria","family":"Zannoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Chiti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincenzo","family":"Scarlato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Chiappori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"398","DOI":"10.3390\/IJMS23010398","article-title":"Metformin Repurposing for Parkinson Disease Therapy: Opportunities and Challenges","volume":"23","author":"Agostini","year":"2021","journal-title":"Ijms"},{"key":"B2","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1089\/OMI.2021.0221","article-title":"Past, Present, and Future of Therapies for Pituitary Neuroendocrine Tumors: Need for Omics and Drug Repositioning Guidance","volume":"26","author":"Aydin","year":"2022","journal-title":"OMICS: A J. Integr. Biol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"100012","DOI":"10.1016\/J.CRPHAR.2020.100012","article-title":"Perspective Insights of Repurposing the Pleiotropic Efficacy of Statins in Neurodegenerative Disorders: An Expository Appraisal","volume":"2","author":"Bhat","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"B4","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1002\/bip.22331","article-title":"Twenty-five Years of Nucleic Acid Simulations","volume":"99","author":"Cheatham","year":"2013","journal-title":"Biopolymers"},{"key":"B5","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1111\/j.1574-6976.2010.00233.x","article-title":"Regulatory Circuits inHelicobacter Pylori: Network Motifs and Regulators Involved in Metal-dependent Responses","volume":"34","author":"Danielli","year":"2010","journal-title":"FEMS Microbiol. Rev."},{"key":"B6","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/J.BMCL.2008.11.113","article-title":"Potent and Selective Inhibitors of Helicobacter pylori Glutamate Racemase (MurI): Pyridodiazepine Amines","volume":"19","author":"Geng","year":"2009","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B7","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3390\/PHARMACEUTICS11120681","article-title":"Repurposing Dihydropyridines for Treatment of Helicobacter pylori Infection","volume":"11","author":"Gonz\u00e1lez","year":"","journal-title":"Pharmaceutics"},{"key":"B8","doi-asserted-by":"publisher","first-page":"541","DOI":"10.4155\/fmc-2017-0181","article-title":"Transcriptional Regulators: Valuable Targets for Novel Antibacterial Strategies","volume":"10","author":"Gonz\u00e1lez","year":"2018","journal-title":"Future Med. Chem."},{"key":"B9","doi-asserted-by":"publisher","first-page":"11294","DOI":"10.1038\/s41598-019-47746-9","article-title":"Identifying Potential Novel Drugs against Helicobacter pylori by Targeting the Essential Response Regulator HsrA","volume":"9","author":"Gonz\u00e1lez","year":"","journal-title":"Sci. Rep."},{"key":"B10","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1053\/j.gastro.2017.04.022","article-title":"Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis","volume":"153","author":"Hooi","year":"2017","journal-title":"Gastroenterology"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcimb.2017.00168","article-title":"Novel and Effective Therapeutic Regimens for helicobacter Pylori in an Era of Increasing Antibiotic Resistance","volume":"7","author":"Hu","year":"2017","journal-title":"Front. Cel. Infect. Microbiol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0924-8579(01)00468-X","article-title":"Metronidazole Resistance in Helicobacter pylori","volume":"19","author":"Jenks","year":"2002","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B13","doi-asserted-by":"publisher","first-page":"183","DOI":"10.4292\/wjgpt.v6.i4.183","article-title":"Antibiotic Treatment forHelicobacter Pylori: Is the End Coming?","volume":"6","author":"Kim","year":"2015","journal-title":"Wjgpt"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2778","DOI":"10.1021\/ci200227u","article-title":"LigPlot+: Multiple Ligand-Protein Interaction Diagrams for Drug Discovery","volume":"51","author":"Laskowski","year":"2011","journal-title":"J. Chem. Inf. Model."},{"key":"B15","doi-asserted-by":"publisher","first-page":"3696","DOI":"10.1021\/ACS.JCTC.5B00255","article-title":"ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J. Chem. Theor. Comput."},{"key":"B16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/S12275-014-3603-5","article-title":"Nontraditional Therapies to Treat Helicobacter pylori Infection","volume":"52","author":"Makobongo","year":"2014","journal-title":"J. Microbiol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"3314","DOI":"10.1021\/ct300418h","article-title":"MMPBSA . Py : An Efficient Program for End-State Free Energy Calculations","volume":"8","author":"Miller","year":"2012","journal-title":"J. Chem. Theor. Comput."},{"key":"B18","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: Automated Docking with Selective Receptor Flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1016\/J.BMCL.2007.04.063","article-title":"Carbonic Anhydrase Inhibitors: The \u03b2-carbonic Anhydrase from Helicobacter pylori Is a New Target for Sulfonamide and Sulfamate Inhibitors","volume":"17","author":"Nishimori","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B20","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1002\/prot.20033","article-title":"Exploring Protein Native States and Large-Scale Conformational Changes with a Modified Generalized Born Model","volume":"55","author":"Onufriev","year":"2004","journal-title":"Proteins"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/srep41063","article-title":"Insight into the Essential Role of the Helicobacter pylori HP1043 Orphan Response Regulator: Genome-wide Identification and Characterization of the DNA-Binding Sites","volume":"7","author":"Pelliciari","year":"2017","journal-title":"Sci. Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3390\/CELLS11020263","article-title":"Tackling the Behavior of Cancer Cells: Molecular Bases for Repurposing Antipsychotic Drugs in the Treatment of Glioblastoma","volume":"11","author":"Persico","year":"2022","journal-title":"Cells"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/IJC.33965","article-title":"Repurposing Autophagy Regulators in Brain Tumors","author":"Petrosyan","year":"2022","journal-title":"Intl J. Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug Repurposing: Progress, Challenges and Recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B25","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3390\/microorganisms10010185","article-title":"Targeting of Regulators as a Promising Approach in the Search for Novel Antimicrobial Agents","volume":"10","author":"Roncarati","year":"2022","journal-title":"Microorganisms"},{"key":"B26","doi-asserted-by":"publisher","first-page":"9891","DOI":"10.1007\/s00253-020-10945-w","article-title":"Helicobacter pylori Treatment in the post-antibiotics Era-Searching for New Drug Targets","volume":"104","author":"Roszczenko-Jasi\u0144ska","year":"2020","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"31","DOI":"10.3390\/PH15010031","article-title":"Ranolazine: An Old Drug with Emerging Potential; Lessons from Pre-clinical and Clinical Investigations for Possible Repositioning","volume":"15","author":"Rouhana","year":"2021","journal-title":"Pharmaceuticals"},{"key":"B28","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1002\/wcms.1121","article-title":"An Overview of the Amber Biomolecular Simulation Package","volume":"3","author":"Salomon-Ferrer","year":"2013","journal-title":"Wires Comput. Mol. Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1128\/JB.187.9.3100-3109.2005","article-title":"Phosphorylation-independent Activity of Atypical Response Regulators of Helicobacter pylori","volume":"187","author":"Scha\u0308r","year":"2005","journal-title":"J. Bacteriol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.mib.2006.08.007","article-title":"Transcriptional Regulatory Networks in Bacteria: from Input Signals to Output Responses","volume":"9","author":"Seshasayee","year":"2006","journal-title":"Curr. Opin. Microbiol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"28637","DOI":"10.1074\/jbc.C100295200","article-title":"A Distinct Meta-Active Conformation in the 1.1-\u00c5 Resolution Structure of Wild-type ApoCheY","volume":"276","author":"Simonovic","year":"2001","journal-title":"J. Biol. Chem."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1021\/acs.jcim.5b00559","article-title":"ZINC 15 - Ligand Discovery for Everyone","volume":"55","author":"Sterling","year":"2015","journal-title":"J. Chem. Inf. Model."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1136\/gutjnl-2015-309252","article-title":"Kyoto Global Consensus Report onHelicobacter Pylorigastritis","volume":"64","author":"Sugano","year":"2015","journal-title":"Gut"},{"key":"B34","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/41483","article-title":"The Complete Genome Sequence of the Gastric Pathogen Helicobacter pylori","volume":"388","author":"Tomb","year":"1997","journal-title":"Nature"},{"key":"B35","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1590\/S0004-28032016000400002","article-title":"Drug Resistance in helicobacter Pylori","volume":"53","author":"Vianna","year":"2016","journal-title":"Arq. Gastroenterol."},{"key":"B36","article-title":"Prioritization of Pathogens to Guide Discovery, Research and Development of New Antibiotics for Drug-Resistant Bacterial Infections, Including Tuberculosis","volume":"148","year":"2017","journal-title":"WHO Rep."},{"key":"B37","doi-asserted-by":"publisher","first-page":"e12857","DOI":"10.1111\/ECI.12857","article-title":"Treatment of Helicobacter pylori Infection: A Clinical Practice Update","volume":"48","author":"Zagari","year":"2018","journal-title":"Eur. J. Clin. Invest."},{"key":"B38","doi-asserted-by":"publisher","first-page":"7848","DOI":"10.3390\/ijms22157848","article-title":"Definition of the Binding Architecture to a Target Promoter of HP1043, the Essential Master Regulator of Helicobacter pylori","volume":"22","author":"Zannoni","year":"2021","journal-title":"Ijms"}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2022.887564\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,12]],"date-time":"2022-05-12T21:23:28Z","timestamp":1652390608000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2022.887564\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":38,"alternative-id":["10.3389\/fmolb.2022.887564"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2022.887564","relation":{},"ISSN":["2296-889X"],"issn-type":[{"type":"electronic","value":"2296-889X"}],"subject":[],"published":{"date-parts":[[2022,5,11]]},"article-number":"887564"}}